De Siqueira, J, Abdul Zani, I, Russell, DA et al. (3 more authors) (2015) Clinical and Preclinical Use of LOX-1-Specific Antibodies in Diagnostics and Therapeutics. Journal of Cardiovascular Translational Research, 8 (8). pp. 458-465. ISSN 1937-5387
Abstract
Lectin-like oxidized low-density lipoprotein receptor-1 (SR-E1, LOX-1, OLR1) was first discovered as a vascular receptor for modified lipoprotein particles nearly 20 years ago. Since then, in vitro and in vivo studies have demonstrated an association between LOX-1, a soluble form (sLOX-1) and a number of diseases including atherosclerosis, arthritis, hypertension and pre-eclampsia. However, converting such discoveries into tools and drugs for routine clinical use is dependent on translational preclinical and clinical studies but such studies have only begun to emerge in the past decade. In this review, we identify the key clinical applications and corresponding criteria that need to be addressed for the effective use of LOX-1-related probes and molecules for patient benefit in different disease states.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Keywords: | Scavenger receptor; LOX-1; Oxidized LDL; Atherosclerosis; Biomarker |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Biological Sciences (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 01 Aug 2016 15:25 |
Last Modified: | 03 Nov 2016 03:59 |
Published Version: | http://doi.org/10.1007/s12265-015-9655-z |
Status: | Published |
Publisher: | Springer Verlag |
Identification Number: | 10.1007/s12265-015-9655-z |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:96532 |